Recursion to buy Rallybio's ownership in jointly developed bone disorder drug
Source: SeekingAlpha
2025-07-08 08:39:40 ET
More on Rallybio, Recursion Pharmaceuticals
- Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable
- Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky
- Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter
- Recursion Pharma to reduce workforce by 20%
- Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026
Read the full article on Seeking Alpha
For further details see:
Recursion to buy Rallybio’s ownership in jointly developed bone disorder drug
Rallybio Corporation
NASDAQ: RLYB
RLYB Trading
-4.71% G/L:
$9.50 Last:
67,232 Volume:
$9.58 Open:
RLYB Latest News
RLYB Stock Data
$25,346,266
4,324,707
0.55%
9
N/A
Biotechnology & Life Sciences
Healthcare
US
New Haven
